Figure 6
From: New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery
Pioglitazone or metformin reduced Plin2 levels in primary hepatocyte cultures via CMA activation. Panels (A,B): Pioglitazone and metformin at pharmacological concentrations significantly increased AMPK Thr172 phosphorylation, (pioglitazone in human primary hepatocytes: from 0.43 ± 0.04 to 1.18 ± 0.26, P = 0.04; metformin in human primary hepatocytes: from 0.43 ± 0.04 to 0.94 ± 0.12, P = 0.005; pioglitazone in rat primary hepatocytes: from 0.81 ± 0.11 to 1.87 ± 0.31, P = 0.03; metformin in rat primary hepatocytes: from 0.81 ± 0.11 to 1.50 ± 0.14, P = 0.01). Panels (C,D): Pioglitazone and metformin at pharmacological concentrations significantly increased LAMP2A protein expression (pioglitazone in human primary hepatocytes: from 2.16 ± 0.21 to 3.40 ± 0.37, P = 0.02; metformin in human primary hepatocytes: from 2.16 ± 0.21 to 3.30 ± 0.36, P = 0.04; pioglitazone in rat primary hepatocytes: from 2.91 ± 0.70 to 4.92 ± 0.90, P = 0.02; metformin in rat primary hepatocytes: from 2.91 ± 0.70 to 5.62 ± 1.11, P = 0.04). Panels (E,F): Pioglitazone and metformin at pharmacological concentrations significantly decreased Plin2 protein expression (pioglitazone in human primary hepatocytes: from 0.67 ± 0.13 to 0.38 ± 0.08, P = 0.02; metformin in human primary hepatocytes: from 0.67 ± 0.13 to 0.30 ± 0.06, P = 0.02; pioglitazone in rat primary hepatocytes: from 0.65 ± 0.11 to 0.41 ± 0.11, P = 0.03; metformin in rat primary hepatocytes: from 0.65 ± 0.11 to 0.39 ± 0.06, P = 0.02). Data are expressed as mean ± SEM (n = 5 controls).
